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Abstract
The study was performed in order to determine whether peripheral blood monocyte in vitro
function, and lymphocyte in vivo activation at diagnosis, was associated with HPV tumor in-
fection status and 15-year survival in head and neck squamous cell carcinoma (HNSCC)
patients. Sixty-five patients from a consecutive cohort of newly diagnosed HNSCCs, togeth-
er with 18 control patients, were included in the study. Monocyte responsiveness was as-
sessed by measuring monocyte in vitro interleukin (IL)-6 secretions after 24 hours of LPS
stimulation in cultures with a serum-free medium. T lymphocyte activation was determined
as the fraction of CD71-positive cells on CD3-positive cells by flow cytometry, whereas HPV
infection was determined by PCR on formalin-fixed paraffin-embedded (FFPE) tumor tis-
sue. Disease-specific survivals and overall survivals were determined 15 years following in-
clusion. HPV-positive HNSCC patients had a lower monocyte LPS-stimulated IL-6
response. A high LPS-stimulated monocyte IL-6 response predicted a decreased survival
rate (P=0.019). A high percentage of CD71-positive T lymphocytes also predicted an im-
paired prognosis (P=0.021). The predictive power of IL-6 monocyte LPS-stimulated re-
sponses was retained when adjusted for age, gender and TNM stage of the patients. The
monocyte and T lymphocyte survival predictions were independent of each other. The sur-
vival was particularly low with a combined high activated monocyte and T lymphocyte sta-
tus. In a multivariate analysis, IL-6 secretion and the percentage of CD71-positive T
lymphocytes both uniquely predicted survival independent of HPV infection status. It is pos-
tulated that the natural and adaptive immune systems are separately and additionally linked
to the clinical aggressiveness of HNSCCs.
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Introduction
Both epidemiological and experimental evidence suggest a link between chronic inflammation
and the development of malignancy [1, 2], in particular when the inflammation is caused by
chronic infection [3]. Chronic inflammation has also been suggested to promote head and
neck squamous cell carcinoma (HNSCC) [4]. Furthermore, the steadily growing knowledge
about the human papilloma virus (HPV) as a pathogen of some HNSCC tumors [5], especially
the oropharyngeal (OP)SCC [6, 7], should encourage the addressing of inflammation in the de-
velopment of HNSCC.
The immune system probably takes part in the eradication of HPV-positive (+) tumor cells
during treatment [8]. The role of the immune system in cases where HNSCC disease is caused
by HPV infection beyond this finding is not well established. Moreover, the potentially differ-
ent roles of the immune system in HPV-negative (-) versus HPV-positive HNSCC patients
have not been established and are therefore of interest to study.
The influx of inflammatory cells into tumors generally indicates a more aggressive clinical
behavior [1]. In the oral cavity, ordinary HNSCCs may serve as examples of the latter phenom-
enon [9]. On the other hand, possibly due to their association with HPV infection, the local in-
flammatory tumor response has long been associated with a better prognosis in OPSCC
patients [10].
The immune system functions as a whole body-integrated system in response to various
types of agents, possibly including tumor cells. In HNSCC patients, immune cells from periph-
eral blood (PB) have, e.g. been shown to be generally responsive to local tumors [4, 11]. Thus,
HNSCCs should be considered as affecting the host immune competent cells. If there are dis-
crepancies in HPV+ and HPV- HNSCC patients with respect to the PB immune responses
have not been extensively studied and warrant further investigations.
High soluble IL-2α receptor levels in serum may predict impaired prognosis in HNSCC pa-
tients [12]. In line with this, we have shown that a high percentage of the PB T lymphocytes
carrying the activation epitope CD69 is associated with an impaired long-term prognosis [13].
If this is also the case for other T lymphocyte activation epitopes, such as CD71 [14], both with
and without reference to the HPV tumor status is not known and has been one of the specific
aims of the present study.
The mononuclear phagocyte (MNP) system, including monocytes, macrophages and some
dendritic cells [15], constitutes a major part of the inflammatory system, both as effector cells
and by the secretion of various cytokines, such as pro-inflammatory cytokines (IL-6) and che-
mokines (MCP-1) [4]. Serum IL-6 levels may predict survival in cancer patients [16], including
both lung cancer [17] and HNSCC [18] patients. In accordance with this, we have shown that a
high IL-6 secretion measured from lipopolysaccharide (LPS)-stimulated PB monocytes from
HNSCC patients predicted an impaired intermediate-term prognosis [19]. It therefore seems
that increased IL-6 levels are a negative prognostic factor in HNSCC patients, although to what
extent this is affected by the HPV infection in the tumor is not known. To help address this
issue in this study, we have evaluated the prognostic power of the present monocyte priming
by studying both LPS-stimulated IL-6 secretion in vitro and these findings by the HPV
infection status.
We have studied the prognosis of newly diagnosed HNSCC patients dependent on the spon-
taneous activation of T lymphocytes in vivo, and the level of monocyte priming in vitro from
the same patients. Both monocyte and lymphocyte functional levels uniquely predicted
HNSCC prognosis both with and without HPV stratification.
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Materials and Methods
Patients
The study comprised consecutive patients hospitalized at the Department of Otolaryngology
and Head and Neck Surgery, Haukeland University Hospital, Bergen, Norway. The patients ei-
ther had squamous cell carcinoma (SCC) (N = 65) or non-cancer diseases of the head and neck
(HN) (N = 18), diagnosed in the period from June 1, 1997 to April 12, 1999. Patients with auto-
immune disease or patients on corticosteroid medications were not included in the study. The
study was approved by the “Regional Committees for Medical and Health Research Ethics,”
Western Norway branch, and each patient gave their written consent before participating in
the study. The primary sites of the carcinomas were: oral cavity (n = 26), oropharynx (n = 19),
hypopharynx (n = 5), larynx (n = 13), maxilla (n = 1) and unknown primary (n = 1). The
mean ± standard deviation (SD) ages of the HNSCC patients were 62.1±10.7 years and 64.4
±10.6 years for the control patients. The TNM stages of the HNSCC patients are shown in
Table 1. The survival of the patients was determined from the Norwegian Population Registry
by a survival time of 15 years. Still, 16 of 65 cancer patients and 10 of 18 controls were alive.
Blood samples
The patients were included in the study at their arrival to the department before any specific
cancer treatment had started. All blood samples were drawn at 7.30 a.m. as a bedside proce-
dure, and each patient was asked to stay in bed until the blood sample was drawn.
Monocyte preparation. Peripheral blood mononuclear cells (PBMC) were separated by
gradient centrifugation with Lymphoprep (Nycomed, Oslo, Norway) as the density gradient
medium. The PBMC yield of 8.5 ml blood was allocated to a 24-well plate (Nunc A/S, Roskilde,
Denmark) with RPMI-1640 (BioWhittaker, Walkersville, MD, USA), supplemented with am-
photericin B (2.5 μg/ml) and glucose (both Sigma, St. Louis, MO, USA), HEPES, L-glutamine (2
mM), penicillin (100 IU/ml), streptomycin (100 μg/ml), sodium bicarbonate, sodium pyruvate
(all from BioWhittaker) and 20% autologous serum (AS) to a total volume of 0.5 ml/well. After
40 minutes of pre-incubation, the adherent monocytes were purified by washing and then cul-
tured in a serum-free medium (UltraCulture; BioWhittaker) with 0.5 ml/well. The method
yields more than 95%monocyte-positive cells by non-specific esterase stain with more than
95% viable cells, as tested by trypan blue stain. In vitro stimulation was provided for 24 hours
by 1 μg/ml lipopolysaccharide (LPS) derived from Escherichia coli (Sigma) before the sample
collection. Moreover, cultures without specific stimulation were used as background controls.
IL-6 analysis. The contents of IL-6 in the supernatants were determined through the use
of an enzyme-linked immuno-sorbent assay (ELISA) kit, manufactured by R&D Systems
Table 1. TNM stages of all included patients.
T stage
0 1 2 3 4 SUM
N stage 0 2 10 12 5 8 37
1 0 0 2 2 3 7
2 0 6 4 4 3 17
3 0 3 1 0 0 4
SUM 2 19 19 11 14 65
All patients were M0 at inclusion.
doi:10.1371/journal.pone.0129724.t001
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(R&D Systems Europe Ltd., Abingdon, Great Britain). All procedures were performed accord-
ing to the specifications from the manufacturer. Briefly, 96-well micro-tither plates (Costar
Corning, NY, USA) were coated overnight at room temperature (RT) with monoclonal mouse
α-human IL-6 capture antibodies. Diluted samples and recombinant human IL-6 standards
were added and incubated for 2 hours at RT, followed by the addition of biotinylated polyclon-
al goat α-human IL-6. The plates were incubated for 20 minutes at RT with streptavidin-
conjugated horseradish peroxidase. Tetra-methyl-benzidine (TMB) (Sigma) and H2O2 were
also used as substrates. Absorbency values were measured at 450 nm using Softmax Pro version
4.0 on an Emax Precision micro-tither plate reader (Molecular Devices, Sunnyvale, CA, USA).
The lower detection level was 9 pg/mL for IL-6.
Flow cytometric determination of percentage positive PBMC cells. Immunophenotyp-
ing was performed on each PBMC specimen using a panel of mAbs conjugated with either
fluorescein isothiocyanate (FITC) or phycoerythrin (PE) fluorochromes. Anti-CD71-FITC
(anti-transferrin receptor) and anti-CD3-PE were obtained from Becton Dickinson, San Jose,
CA, USA. Samples with fluorochrome-conjugated nonspecific isotype-matched mAbs were
used as negative controls. The cell analysis was performed on a Coulter Epics XL flow cytome-
ter (Coulter Electronics, Ltd, Luton, Great Britain) equipped with an air-cooled 15 mW argon-
ion laser operating at 488 nm. In each cell preparation, gates were set on the lymphocytes using
light scatter characteristics and 5,000 cells were analyzed. The fluorescence data were expressed
as dual parameter histograms of FITC versus PE fluorescence. Moreover, fluorochrome com-
pensation was adjusted utilizing normal control peripheral blood leukocytes labeled with
FITC-coupled anti-CD4 and PE-coupled anti-CD8. Four-quadrant analyses, with markers set
on the isotype controls, were further used to determine the percentage of positive cells for each
set of mAbs.
DNA isolation. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) spec-
imens. These were tissues from primary HN tumors in diagnostic or surgical samples, or from
lymph node metastatic lesions. Three 10 μm-thick FFPE sections were deparaffinized in xylene
and ethanol, and digested overnight in an ATL buffer and Proteinase K (Qiagen GmbH, Hil-
den, Germany) at 56°C. DNA was extracted using the EZNA tissue DNA kit (Omega Bio-Tek,
Norcross, GA, USA). The DNA concentration was measured on a NanoDrop spectrophotome-
ter (Nanodrop, Minneapolis, MN, USA). HPV-negative DNA (control) samples were isolated
from blocks provided from human large bowel FFPE tissue samples. For every fourth-sectioned
ENT specimen, a control (HPV-negative) block was sectioned as internal negative controls to
test for the potential risk of HPV contamination in the procedure. All interspersed negative
sample controls had to be negative to accept any positive HPV PCR results.
All tumor samples were reviewed by an expert in pathology (OKV), and representative
FFPE tissue samples were selected for HPV DNA analysis.
HPV DNA detection. We have previously published our method in detail [20]. For the
detection of HPV, DNA standard Gp5+/Gp6+ primers were used [21]. The PCR reaction mix
consisted of a Multiplex Mastermix PCR kit (Qiagen GmbH, Hilden, Germany), 2 μl of primer
mix and 2 μl of DNA run in a volume of 20 μL. The samples were inactivated by heating (95°C)
for 15 minutes and then run for 38 cycles at 94°C for 45 seconds, 43°C for 90 seconds and 72°C
for 90 seconds, and lastly 72°C for 10 minutes. Samples with known HPV DNA were included
as positive (PCR) controls, whereas the substrate DNA was omitted in the negative
(PCR) controls.
The PCR products were separated and visualized on a 3% agarose gel. Only samples with
distinct PCR bands were considered positive for HPV and further processed for HPV subtype
identity by DNA sequencing. The PCR products were first purified by incubation with ExoStar
(GE Healthcare, Buckinghamshire, UK) at 37°C for 15 minutes, followed by enzyme
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inactivation at 80°C for 15 minutes. The purified PCR products were then prepared for se-
quencing using the same primers as for the initial PCR reaction in combination with a BigDye
Terminator v1.1 Cycle Sequencing kit (Life Technologies, Foster City, CA, USA). Before analy-
sis on a 3130XL Genetic Analyzer (Life Technologies, Foster City, CA, USA), the products of
the sequencing reaction was purified using a BigDye Xterminator kit (Life Technologies, Foster
City, CA, USA). The HPV DNA sequences were identified using the NCBI BLAST database,
and more than a 98% homology was observed with NCBI BLAST.
HPV status of included patients. Ten HNSCC patients from the original cohort were
positive for HPV DNA, all with tumors originating from oropharynx [13]. These tumors origi-
nated from the tonsils (n = 7), the basis of the tongue (n = 2) or the lateral wall of the orophar-
ynx (n = 1). We lacked the actual biopsies from three HNSCC patients of the present series in
order to determine HPV status. None of these patients had tumors originating from the oro-
pharynx, so we have therefore designated them as HPV- patients during the following
reported analyses.
Statistical analysis
The statistical program package IBM SPSS Statistics for Windows was employed (Rel.19.0.0.
2009. SPSS Inc.). Numbers are given as mean ± SD. The groups were compared by Chi square
tests, while survival analyses were performed by Cox regression or Kaplan-Meier analyses. In
some analyses, HNSCC patient monocyte responsiveness and T lymphocyte activation levels
were dichotomized as high or low responders by the median value. Statistical significance was
considered if P<0.05.
Results
HNSCC patient prognosis by HPV infection status
A strong trend was shown towards better survival among the HPV+ patients (P = 0.067) (Fig 1).
Monocyte IL-6 secretion in control versus HNSCC patients
Analyses showed that the supernatant IL-6 levels in cultures from control versus HNSCC pa-
tients were not statistically different, both as measured with and without LPS stimulation. Simi-
lar results were obtained when the background IL-6 levels were subtracted (Table 2). No
difference was observed as to the percentage of CD71-positive T lymphocytes between the con-
trol and HNSCC patients (Table 2).
Monocyte IL-6 secretion in HNSCC HPV+ versus HNSCC HPV- patients
Analyses showed that the supernatant IL-6 levels in cultures from HNSCC HPV- patients
(55333±34550 pg/ml) were higher compared to the HNSCC HPV+ (24020±33039 pg/ml) pa-
tients (P = 0.002). Similar results were obtained when the background IL-6 levels were sub-
tracted (Table 3).
Prognostic value of monocyte in vitro activation
Among the HNSCC patients, the IL-6 secretion level following in vitro LPS stimulation of
monocytes was found to predict the 15-year prognosis when analyzed by Kaplan-Meier
(P = 0.009) (Fig 2). High values of IL-6 secretion predicted a low survival. This was valid, both
with stimulated values directly analyzed and analyzed with stimulated values in which back-
ground levels were subtracted. When studied adjusted by age, gender, TNM stage and HPV sta-
tus, the IL-6 secretion still predicted the 15-year prognosis (RR = 2.32; CI 1.18–4.55; P = 0.015)
Monocyte and T Lymphocyte Activation Predict Survival in HNC Patients
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(Table 4). Among the HNSCC patients, Kaplan-Meier analyses showed that the LPS-stimulat-
ed IL-6 secretion rate predicted the 15-year survival when stratified by HPV status (P = 0.019),
and only including the HPV-negative patients (P = 0.013) (Fig 2).
Prognostic value of PB lymphocyte activation status
The PB lymphocyte activation was investigated by flow cytometry by the determination of per-
centage of T cells exposing the activation epitope CD71 on the surface. When gated on lym-
phocytes, a high CD71 level predicted an adverse HNSCC patient 15-year survival (P = 0.020)
(Fig 3). No such prediction was determined among the controls (Fig 3). When stratified by
HPV status, a 15-year survival prediction was still obtained among the HPV-negative patients
(P = 0.04) (Fig 3). An adjustment for age, gender and TNM stage, as well as HPV status, did
Fig 1. Overall survivals of the cohort of included HNSCC patients stratified by whether there were HPV-positive or HPV-negative tumors.Cohort:
56 HPV-negative and 9 HPV-positive HNSCC patients. Statistics by Kaplan-Meier analysis (Log rank test).
doi:10.1371/journal.pone.0129724.g001
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not remove the prediction of the CD71 T lymphocyte-positive percentage for prognosis (RR =
2.12; CI 1.13–3.96; P = 0.019) (Table 3).
Prognostic value of combined PB lymphocyte and monocyte activation
status
If the CD71 T lymphocyte activation and IL-6 monocyte secretion, both dichotomized, were
analyzed simultaneously using a Cox regression analysis and adjusted by age, gender, TNM
stage and HPV status, both parameters had a significant prognostic impact on survival; i.e. IL-
6 with RR = 3.25 (CI: 1.49–7.08; P = 0.003) and CD71/CD3 with RR = 2.99 (CI: 1.39–6.42;
P = 0.005) (Table 5). Furthermore, these marker binomial scores were combined to one vari-
able as a sum score. When analyzing the 15-year survival by including this variable, a highly
significant negative prediction of the 15-year survival was obtained among the HNSCC pa-
tients (P = 0.002) (Fig 4). If stratified by HPV, a significant survival prediction was still ob-
tained (P = 0.004) (Fig 4). With adjustments for age, gender, TNM stage and the HPV status of
the patient, the combined activation variable still predicted survival (RR = 3.11, CI: 1.68–5.75;
P = 0.000) when analysed by a Cox regression survival analysis (Table 4).
Table 2. HNSCC or control patient PB CD71 positivity (%) on T lymphocytes (CD3-positive cells) or monocyte 24 hours in vitro LPS-stimulated IL-6
secretion (pg/ml).
Control HNSCC p-value
Mean SD Range Mean SD Range
Monocyte spontaneous in vitro 24-hour cytokine secretion
IL-6 8210 13039 1–44747 3389 6409 0–26463 n.s.
Monocyte LPS-stimulated in vitro 24-hour cytokine secretion
IL-6 51794 39837 7135–131011 51347 35653 1–139794 n.s.
Monocyte LPS-stimulated in vitro 24-hour net cytokine secretion
IL-6 43588 34702 6857–127575 47835 33865 0–133014 n.s.
PB T lymphocytes CD71+ (%)
CD71/CD3 8.3 4.6 1.0–8.3 9.2 6.0 1.6–25.4 n.s.
doi:10.1371/journal.pone.0129724.t002




Mean SD Range Mean SD Range
Monocyte spontaneous in vitro 24-hour cytokine secretion
IL-6 3582 6732 0–26463 2011 3280 1–9286 n.s.
Monocyte LPS-stimulated in vitro 24-hour cytokine secretion
IL-6 55333 34550 8117–139794 24020 33039 1–93947 .002
Monocyte LPS-stimulated in vitro 24-hour net cytokine secretion
IL-6 51602 33003 275–133014 22008 29962 0–84661 .007
PB T lymphocytes CD71+ (%)
CD71/CD3 9.6 6.2 1.6–25.4 7.0 4.2 1.6–14.5 n.s.
doi:10.1371/journal.pone.0129724.t003
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If studied by disease-specific survival (DSS), the combined variable predicted DSS among
the HPV-negative patients (P = 0.016) (Fig 5). When including all HNSCC patients available
adjusted by age, gender, TNM stage and HPV status, the sum score still predicted DSS
(RR = 5.55, CI: 2.31–13.37; P = 0.000) (Table 6).
Fig 2. Overall survival plots by IL-6 in vitro secretion from LPS-stimulated monocytes. HNSCC versus control patients (upper panel) and HNSCC
patients adjusted by whether HPV infected tumor (lower panel). IL-6 in vitro secretion of purified monocytes determined by ELISA analyses following 24-hour
LPS stimulation. Cytokine levels with background subtracted dichotomized by median value to low (continuous line) or high (hatched line) response. Cohort
(upper panel): 55 HNSCC and 18 control patients. Cohort (lower panel): 48 HPV-negative and 7 HPV-positive HNSCC patients. Statistics by Kaplan-Meier
analyses (Log rank test).
doi:10.1371/journal.pone.0129724.g002
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Discussion
In this study we have examined monocyte responsiveness, as well as lymphocyte activation
with cells from PB from controls and HNSCC patients. We have investigated monocyte re-
sponsiveness as measured by in vitro LPS-stimulated responses in monocytes (IL-6 secretion),
and lymphocyte activation by the presence of an early activation epitope on the surface of PB T
lymphocytes (CD71). Patients with high monocyte responsiveness had a lower 15-year survival
than patients with a low such response. Likewise, a high PB T lymphocyte activation state as
measured by the CD71 percentage on the surface, predicted decreased 15-year survival. The
measured monocyte and lymphocyte factors independently predicted prognosis and the data
were also stratified by HPV tumor infection status without any change in the results.
Many different carcinoma diseases rising from the aero-digestive tract are suggested to be at
least partially dependent on inflammation-derived signals [3], e.g. via cytokine secretion [22].
This applies to both lung [2] and gastro-intestinal cancer [23].
Monocytes are members of the MNP system [4], which secrete such cytokines in particular
following activation [24, 25]. Monocyte function may be assessed by measuring cytokine secre-
tion after in vitro stimulation of the TLR-4 receptor [26]. Such stimulation promotes the secre-
tion in particular of pro-inflammatory interleukins (IL-1β, IL-6, TNF-α) [25], and modulates
chemokine (MIP-1α/β, MCP-1) secretion [24].
IL-6 is a pluripotent cytokine with mostly stimulatory functions. IL-6 may, e.g. act as an au-
tocrine or paracrine tumor growth factor [16], but also as an anti-apoptotic agent [27] on can-
cer cells, as is suggested to be the case in oral cavity cancer [28]. We have previously shown
that high levels of IL-6 secreted from PB monocytes stimulated in vitro through the TLR-4
Table 4. HNSCC patient Cox regression 15-year overall survival analyses dependent onmonocyte,
lymphocyte and combinedmonocyte/lymphocyte function.
Univariate
95% CI for HR
HR Lower Upper Sig.
IL-6* 2.31 1.20 4.41 .012
CD71/CD3* 2.05 1.10 3.81 .023
Sum score** 2.15 1.30 3.56 .003
Bivariate (HPV-adjusted)
95% CI for HR
HR Lower Upper Sig.
IL-6* 2.07 1.07 3.98 .030
CD71/CD3* 2.04 1.10 3.78 .024
Sum score** 2.01 1.21 3.33 .007
Multivariate (Age, gender, TNM stage, and HPV)
95% CI for HR
HR Lower Upper Sig.
IL-6* 2.32 1.18 4.55 .015
CD71/CD3* 2.12 1.13 3.96 .019
Sum score** 3.11 1.68 5.75 .000
HR: Hazard ratio.
CI: Confidence interval.
* = binomially scored
** = Sum score: IL-6 + CD71/CD3 (both binomially scored)
doi:10.1371/journal.pone.0129724.t004
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receptor herald a decreased intermediate-term survival [19]. In this updated study, a high IL-6
secretion still predicted survival following 15 years of observation. We have previously shown
that monocytes are stimulated to secrete IL-6 upon HNSCC tumor co-culture [4]. The strength
of this stimulation also yielded prognostic information [29], and the results suggest that IL-6
reflect an importance of the degree of inflammation upon HNSCC disease.
Fig 3. Overall survival plots dependent on percentage CD71 expression on T lymphocytes (CD3-positive cells). HNSCC versus control patients
(upper panel) and HNSCC patients adjusted by whether HPV infected the tumor (lower panel). Percentages determined by flow cytometry on fresh PBMCs
harvested from the patients. Percentages dichotomized by median value to low (continuous line) or high (hatched line). Cohort (upper panel): 58 HNSCC and
16 control patients. Cohort (lower panel): 50 HPV-negative and 8 HPV-positive. Statistics by Kaplan-Meier analyses (Log rank test).
doi:10.1371/journal.pone.0129724.g003
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The measurement of the in vivo exposure of activation surface molecules on PB lympho-
cytes from HNSCC patients may be used as a marker for a general in vivo activation of the
adaptive immune system [30]. We have previously shown that an increased percentage of these
activation-related epitopes on T lymphocytes predicted a decreased survival [31]. This updated
long-term survival study shows that a high CD71 percentage of positive T lymphocytes pre-
dicted a decreased survival. This is further in accordance with the results of Starska [32] and
Millrud [33].
We have presently shown that the monocyte function was dependent on HPV status. It has
been suggested that the immune system participates in the treatment-related clearance of
HNSCC, particularly with HPV+ tumors [8]. A future aim would therefore be to study the im-
mune system and tumor interaction more thoroughly and throughout the treatment of HPV
+ versus HPV- HNSCC patients.
HPV+ HNSCC patients have a better prognosis by responding better to treatment than pa-
tients with HPV-negative tumors [34]. By stratifying survival analyses with HPV status, we
have shown that both the shown lymphocyte and monocyte prognostic values were valid irre-
spective of HPV infection status. The findings support that the degree of inflammation is an
important factor as to HNSCC prognosis, especially in HPV-negative patients, because the
number of patients with HPV infection was currently too low to draw any firm conclusions.
IL-6 has been shown to be an inflammation-related growth promoter in many different can-
cer growth processes [16], but also in processes such as atherosclerosis and autoimmune dis-
ease [16]. Hence, it is conceivable that the shown IL-6 prediction also reflects a wider co-
morbidity panorama than the HNSCC disease only. This should be investigated.
Measured monocyte activation responses, as well as the lymphocyte activation level, re-
flected the prognosis also when adjusted for TNM stage. Thus, the level of disease at diagnosis
did not affect the present prognostic findings.
The monocyte and lymphocyte prognostic power has been shown to be independent of
each other in the current investigation. This could be interpreted that the natural immune sys-
tem, i.e. the MNP system, and the adaptive immune system are independently affected by the
cancer disease. We have previously shown the same to be the case with stimulated monocyte
MCP-1 secretion combined with T lymphocyte CD69 expression [13]. For this reason, several
individual lines of measurement show similar results. To the best of the authors’ knowledge,
Table 5. HNSCC patient Cox regression survival analysis dependent on overall 15-year survival ac-
cording to monocyte in vitro LPS-stimulated secretion of IL-6 and CD71 percentage expression on T
lymphocytes adjusted by age, gender, TNM stage and whether HPV tumor infection.
HR 95% CI for HR
Lower Upper Sig.
Age 1.05 1.01 1.10 .029
Gender 3.59 0.88 14.65 .075
T stage 2.19 1.48 3.26 .000
N stage 1.57 1.09 2.25 .015
HPV (±) 0.81 0.17 3.95 .792
IL-6* 3.25 1.49 7.08 .003
CD71/CD3* 2.99 1.39 6.42 .005
HR: Hazard ratio.
CI: Confidence interval.
* = binomially scored
doi:10.1371/journal.pone.0129724.t005
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this is among the first studied cohort in which unique survival predictions associated with PB
natural and adaptive immune systems have been shown to independently predict prognosis in
HNSCC patients. An especially interesting finding is that if the activation of both the natural
and adaptive immune system were present, the prognosis was found to be particularly grim.
This suggests a fatal consequence of combined lymphocyte activation and MNP priming.
Fig 4. Overall survival according to low/high IL-6 monocyte secretion added to low/high CD71 T lymphocyte expression.HNSCC/control patients
(upper panel) and HNSCC patients with HPV adjustment (lower panel). Monocytes cultured as in Fig 2 and lymphocytes analyzed as in Fig 3. Patients
allocated to low IL-6 and CD71 (blue continuous line), low IL-6 or CD71 (red semi-hatched line) or both high IL-6 and CD71 (orange hatched line). Cohort
(upper panel): 48 HNSCC and 16 control patients. Cohort (lower panel): 42 HPV-negative and 6 HPV-positive HNSCC patients. Statistics by Kaplan-Meier
analyses (Log rank test).
doi:10.1371/journal.pone.0129724.g004
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It is generally held that virus-associated inflammation may be beneficial to the host [35],
whereas inflammation caused by irritants and/or tumor cell-derived molecules have the oppo-
site relation [36] to an established tumor. Our results suggest, at least in part, a more complex
association than is currently often held. The implications of studying both general and local
tumor immunity in cancer patients should be further studied.
Vaccination by the use of dendritic-pulsed cells has attracted a considerable amount of at-
tention as a cancer treatment [37]. The fact that the immune system seems to be affected in
HNSCC patients suggests that such therapy, specifically with HPV-related antigens, should be
Fig 5. HPV adjusted disease-specific survival plot according to low/high IL-6 secretion added to low/high CD71 expression.Monocytes cultured as
in Fig 2 and lymphocytes analyzed as in Fig 3. Patients allocated to low IL-6 and CD71 (blue continuous line), low IL-6 or CD71 (red semi-hatched line) or
both high IL-6 and CD71 (orange hatched line). Cohort: 42 HPV-negative and 6 HPV-positive HNSCC patients. Statistics by Kaplan-Meier analysis (Log rank
test).
doi:10.1371/journal.pone.0129724.g005
Table 6. HNSCC patient Cox regression survival analysis dependent on disease-specific survival ac-
cording to monocyte in vitro LPS-stimulated secretion of IL-6 and CD71 percentage expression on T
lymphocytes sum score adjusted by age, gender, TNM stage, and whether there was HPV tumor
infection.
HR 95% CI for HR
Lower Upper Sig.
Age 1.07 1.01 1.13 .031
Gender 3.92 0.69 22.38 .125
T stage 3.23 1.84 5.69 .000
N stage 2.43 1.45 4.05 .001
HPV (±) 2.90 0.27 30.86 .379
Sum score* 5.55 2.31 13.37 .000
HR: Hazard ratio.
CI: Confidence interval.
* = Sum score: IL-6 + CD71/CD3 (both binomially scored)
doi:10.1371/journal.pone.0129724.t006
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investigated further. Future studies may also explore the use of α-IL-6 antibodies and T lym-
phocyte inhibition as adjuvant treatments of the HNSCC disease.
Conclusions
We have shown that monocyte function may be dependent on HPV infection status in
HNSCC patients. Increased LPS-stimulated monocyte IL-6 secretion and a high activation of T
lymphocytes uniquely predicted impaired HNSCC prognosis. The negative prognostic values
were independent of TNM stages and HPV infection status. Thus, monocytes and lymphocytes
seem to play an important role with respect to the clinical outcome in HNSCC patients.
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